Work

Abstract B194: Phase 1 relative bioavailability study of a prototype oral solution (OS) formulation of the investigational Aurora A kinase (AAK) inhibitor alisertib (MLN8237) in reference to a powder-in-capsule (PIC) formulation in patients with advanced solid tumors.

Year: 2011

Type: conference-abstract

Source: Molecular Cancer Therapeutics

DOI: 10.1158/1535-7163.targ-11-b194

Authors: Gerald S. Falchook, John Sarantopoulos, Razelle Kurzrock, Alain C. Mita, Siqing Fu, Monica M. Mita, Xiaofei Zhou, Catherine Milch, JungAh Jung, Karthik Venkatakrishnan, Lee S. Rosen

Institutions: The University of Texas MD Anderson Cancer Center, The University of Texas at San Antonio Health Science Center, Takeda Oncology (United States)

Language: English

Topic: Pharmaceutical studies and practices

Subfield: Pediatrics, Perinatology and Child Health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2061160428

Cites:

Cited by: 1

Related to: 10